First-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the 2026 Precision Medicine World Conference
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Kennedy brings seven years of public company CFO experience
Full Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year Expects Full Year 2026 Revenue of $420 Million to $444 Million
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...
AlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCT Ultra‑Sensitive, Non‑Invasive Surveillance...
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...
Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation...
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value...